The Efficacy of Tislelizumab Combined With Albumin-bound Paclitaxel and Platinum-based Chemotherapy in Patients With KRAS-mutated Lung Cancer

Inclusion Criteria: 1. Ages 18-75 years (inclusive), regardless of gender; 2. Locally advanced (Stage IIIB, IIIC) or metastatic (Stage IV) non-small cell lung cancer (NSCLC) confirmed by histology as inoperable for curative intent (according to the 8th edition of the IASLC TNM staging system); 3. Or histologically confirmed inoperable mixed small cell lung cancer containing non-small cell lung cancer components; 4. KRAS gene mutation-positive; 5. KRAS mutation-positive lung cancer not amenable to radical surgery, treated with tislelizumab in combination with nab-paclitaxel and platinum chemotherapy. Exclusion Criteria: 1. Patients with incomplete key baseline information and treatment data. 2. Patients who refuse to provide written informed consent (ICF).